Mirati Reports Positive Topline Data From Phase 2 Study With Adagrasib; Names David Meek CEO

Mirati Therapeutics, Inc. (MRTX) reported positive topline results from the potentially registration-enabling cohort of the phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with KRAS G12C-Mutated advanced non-small cell lung cancer. In the intent-to-treat population, the study showed adagrasib 600mg BID showed an objective response rate of 43% and a disease control rate of 80%. The safety and tolerability profile was consistent with previously reported findings for adagrasib.

Also, the company reported updated findings from the phase 1/1b KRYSTAL-1 study evaluating adagrasib 600mg BID in all 19 patients enrolled with KRASG12C-mutated advanced NSCLC as of the June 15, 2021 data cutoff. The investigator assessed objective response rate was 58% in this study.

The company looks forward to submitting its New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2021.

Separately, Mirati Therapeutics announced the appointment of David Meek as Chief Executive Officer, effective immediately. David Meek most recently served as president, CEO and board member of FerGene. Charles Baum will continue to lead the research and development organization as president, founder and head of R&D.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT